CarThera

Executive Summary

CarThera is a Paris-based clinical-stage medical device company pioneering implantable ultrasound technology to temporarily open the blood-brain barrier (BBB). Its lead device, SonoCloud, is designed to enhance drug delivery to the brain for severe disorders such as glioblastoma and Alzheimer's disease. The BBB is a major obstacle in treating brain conditions, as it restricts the passage of most therapeutics. CarThera's approach uses low-intensity ultrasound to non-invasively disrupt the BBB, allowing higher concentrations of chemotherapy or immunotherapy to reach tumors or diseased tissue. The company was founded in 2010 and has advanced to Phase 2 clinical trials, primarily evaluating SonoCloud in recurrent glioblastoma patients. The technology has the potential to transform treatment paradigms across multiple neurological indications. CarThera's current focus is on generating pivotal data from its ongoing Phase 2 study in glioblastoma, which could support regulatory approval in Europe and the US. The company also has preclinical programs exploring SonoCloud for Alzheimer's disease, where improved drug delivery could enhance the efficacy of amyloid-targeting antibodies. Strong safety and efficacy results from the GBM trial would be a major catalyst, potentially attracting pharmaceutical partnerships for combination therapies. The company benefits from a strong intellectual property portfolio and academic collaborations. However, as a private entity, CarThera relies on venture funding and grants to finance its operations. Key upcoming milestones include interim data readouts and potential strategic alliances.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Trial Results for SonoCloud in Glioblastoma70% success
• Q2 2026FDA Breakthrough Device Designation for SonoCloud65% success
• Q3 2026Strategic Partnership for Alzheimer's Disease Program50% success